Zevra Therapeutics, Inc. (ZVRA)

In the past six months, ZVRA's stock has trended upwards by 24.86%. A significant event impacting the stock price was the company's strong first-quarter 2026 financial results, reported on May 6, 2026. Zevra Therapeutics reported a net income of $37.9 million, or $0.60 per diluted share, surpassing analyst expectations. Net revenue surged to $36.2 million, a 78% increase year-over-year, driven by robust sales of MIPLYFFA and contributions from other revenue streams. The strategic divestiture of the SDX portfolio for $50.0 million, which generated $40.5 million in net proceeds in Q1 2026, enabled the company to fully prepay its $63.1 million term loan, achieving a debt-free status with $236.8 million in cash, cash equivalents, and securities as of March 31, 2026. Following the earnings announcement, Zevra's stock price increased by 6.03% in aftermarket trading.

Based on historical stock price data, there appears to be some seasonality in ZVRA's stock performance, with May and June showing higher probabilities of positive returns. However, this likely reflects investor sentiment or broader market trends rather than direct demand seasonality for Zevra Therapeutics' products. As a company focused on rare diseases, the demand for its therapeutics is generally driven by ongoing patient needs rather than seasonal fluctuations.

Zevra Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for rare diseases. The company utilizes its Ligand Activated Technology platform for product development. Its major commercial products include MIPLYFFA for Niemann-Pick disease type C (NPC), OLPRUVA for urea cycle disorders, and royalties from AZSTARYS for ADHD. Zevra's pipeline features lead product candidate KP1077, in Phase 3 clinical trials for idiopathic hypersomnia and narcolepsy, and Celiprolol, an investigational product candidate in Phase 3 clinical trials for vascular Ehlers-Danlos syndrome (VEDS).

Zevra Therapeutics, Inc. has its global corporate headquarters in Boston, Massachusetts, with additional corporate offices in Celebration, Florida, and Frederiksberg, Denmark. MIPLYFFA is marketed in the U.S. Zevra is pursuing European market penetration for arimoclomol, with a Marketing Authorisation Application under review by the EMA, and has a Global Expanded Access Program (EAP) to broaden access to arimoclomol in select territories beyond Europe.

Zevra Therapeutics maintains a positive brand reputation, driven by its focus on rare diseases and strong financial performance. The company is described as purpose-driven and patient-centric, committed to bringing life-changing therapies to patients with limited or no treatment options. Wall Street analysts are overwhelmingly bullish on Zevra, with a "Strong Buy" consensus rating and an average twelve-month price target suggesting significant upside potential. This reflects confidence in the company's rare disease portfolio and strengthened financial position following strategic moves like the divestiture of the SDX portfolio and debt elimination.

Zevra Therapeutics, Inc. has a diverse ownership structure, including 157 institutional owners and shareholders holding a total of 40,114,155 shares. Major institutional shareholders include BlackRock, Inc., Woodline Partners LP, Vanguard Group Inc, Fmr Llc, Nantahala Capital Management, LLC, State Street Corp, Geode Capital Management, Llc, Caption Management, LLC, AIGH Capital Management LLC, and Morgan Stanley. Institutional investors own approximately 14.64% to 25.38% of the company's stock. Insiders hold 1.44% of the stock, while public companies and individual investors collectively own 73.18%. Hedge funds own 14% of Zevra Therapeutics.